Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes

16 Oct 2018

Abstract excerpt

Abstract There is a paucity of data regarding the impact of mutations on outcomes in accelerated-phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs). Moreover, it is unknown whether mutational status affects survival, as seen in chronic-phase MPNs. Therefore, we performed a retrospective analysis of all patients treated at our institution with AP/BP MPNs (N = 122; AP = 14; BP = 108) to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30327374
DOI: 10.1182/bloodadvances.2018021469

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomesPMID 30327374Read ↗

Genetic evolution of myeloproliferative neoplasms from chronic phase to blastic phase: An analysis of 46 paired samplesSemantic proximity Read ↗

Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.Semantic proximity Read ↗

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53.Semantic proximity Read ↗

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.Semantic proximity Read ↗

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Accelerated Phase of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy.Semantic proximity Read ↗

Accelerated and Blast Phase Myeloproliferative Neoplasms.Semantic proximity Read ↗

A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.